Aminotadalafil

• Dry fill capsules (20 mg, 60 count, 1.2 g total)
• Dry fill capsules (5 mg, 60 count, 300 mg total)
• 30 mL liquid solution (20 mg per mL, 600 mg total)
• 1 gram powder

• PDE5 inhibition and cGMP signaling that increases nitric oxide mediated vasodilation and smooth muscle relaxation, supporting erection quality and blood flow endpoints in studied models.
• Vascular resistance reduction signals that contribute to lower blood pressure observations as a commonly discussed downstream effect in PDE5 inhibition research.
• Lower urinary tract and prostate related smooth muscle modulation commonly discussed in benign prostatic hyperplasia adjacent research contexts.

Aminotadalafil is commonly studied for

• Erectile function and erection quality endpoints via enhanced blood flow signaling in vascular models
• Prostate health markers commonly investigated in benign prostatic hyperplasia type research paradigms
• Vasodilation and blood flow signals relevant to skeletal muscle perfusion and pump adjacent endpoints in performance research contexts
• Blood pressure modulation observations, particularly in models where baseline vascular resistance is elevated

Commonly monitored observations in PDE5 inhibition research include

• Headache signals
• Low blood pressure and dizziness markers
• Indigestion observations
• Flushing
• Vision change signals
• Priapism in rare model contexts, flagged as an urgent monitoring endpoint when observed